Cooley M&A

JANUARY 22, 2025

This approach, combining M&A and initial public offering (IPO) preparations on parallel tracks, allows companies to maximize optionality in an uncertain market. billion acquisition of Catalent, a leader in contract manufacturing for cell and gene therapies, stands out as the largest healthcare deal of 2024.

M&A 64

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 64

Francine Way

JULY 8, 2017

Many of these causes have their equivalences to the reasons behind the sale of a company (also known as a divestiture): Liquidity: As the equity holding period matured, investors (private equity funds behind companies) will look to sell.

M&A 130

M&A Acquisitions Sale Investment 130

Growth Business

JULY 11, 2023

He should know; for his first venture he spent a year doing the rounds before successfully raising just over £1 million from legendary investor Jon Moulton (who rejected him the first time). Once you’ve made money for investors, it’s a different story.’ million can be raised by investors when they pool their resources,’ they said.

Finance 75

Finance Finance Business Debt 75

Focus Investment Banking

FEBRUARY 25, 2024

First, there’s the ability to raise substantial capital by issuing shares to the public in an initial public offering (IPO), as well as secondary offerings. Lastly, going public is a liquidity event for the founders and early investors, allowing them to cash in on their success.

Private Equity 52

Private Equity IPO Equities Public Trading 52

Cooley M&A

JANUARY 25, 2023

Amid depressed valuations, biotechnology companies also saw an increasing number of demands from activist investors that in certain cases led to more deal activity. Let’s dig in. It’s a more challenging market environment right now than we’ve seen in many years,” said Charlie Kim , who co-chairs Cooley’s capital markets practice.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40